In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

The temporary spending bill that the House and Senate approved last night will keep the federal government operating through ...

The boxed warning follows a safety warning the FDA issued in September about the risk of liver injury from the use of Veozah ...

Although the primary endpoint was not met in a phase 2 study of women who used CBD before a scan, researchers say CBD does ...

If approved, Molbreevi could be the first FDA-approved treatment for patients with autoimmune pulmonary alveolar proteinosis, ...

Some muscles are resistant to the loss of motor neurons seen in patients with spinal muscular atrophy, and new research has ...

Now at the highest percentage in over a decade, this number has rebounded from 42% in 2013 during the rollout of the ...

Tryngolza is once-monthly, subcutaneous RNA-targeted therapy and is expected to be available by the end of the year with a ...

The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

A new study shows that nearly 90% of patients with moderate-to-severe atopic dermatitis (AD) reported their condition ...

Women are more than twice as likely to develop post-traumatic stress disorder than men, and a new study demonstrates for the ...